“…Still, studies on resilience in BC patients had a wide heterogeneity of the BC patients. While some studies assessed the resilience of EBC patients during active oncology treatment [ 25 , 26 , 27 , 29 , 35 ], others assessed resilience among BC survivors [ 17 , 28 , 31 , 32 , 35 , 36 ], and few combined early and metastatic BC patients [ 15 , 16 , 24 , 37 ]. Furthermore, very few studies were designed with a control group [ 29 , 32 , 33 , 35 , 38 ], or included a BC group that consisted of early and metastatic BC patients.…”